Amarin's Vascepa Shows Reduced Cardiovascular Events in Kidney Patients in Latest Study

Eric Volkman, The Motley Fool
·2 min read
Amarin's Vascepa Shows Reduced Cardiovascular Events in Kidney Patients in Latest Study
Amarin's Vascepa Shows Reduced Cardiovascular Events in Kidney Patients in Latest Study

Amarin (NASDAQ: AMRN) released clinical trial results Monday that showed its Vascepa heart medicine effectively reduced cardiovascular events in patients with decreased kidney function. The late-stage trial is a component of the company's REDUCE-IT studies aimed at gauging Vascepa's effect on at-risk patient populations. "We continue to see the consistency in benefit and safety of Vascepa administration across various at-risk patient populations, including across varying degrees of renal function," the company quoted its chief scientific officer, Steven Ketchum, as saying.